The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Wearable-derived physical activity monitoring with AI-based detection of treatment-related adverse events during neoadjuvant chemotherapy for early breast cancer: TRACK-BC.
 
Nobuhiro Shibata
Honoraria - Bristol-Myers Squibb K.K.; Chugai Pharma; Daiichi Sankyo Co., Ltd.; Eisai; Kyowa Kirin Co., Ltd.; Lilly Japan; Merck; MSD K.K.; Nippon Kayaku; Pfizer
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo Co., Ltd.; Kyowa Kirin Co., Ltd.
Research Funding - AstraZeneca Japan (Inst); Daiichi Sankyo Co., Ltd. (Inst); MSD K.K. (Inst)
 
Yukinori Ozaki
Honoraria - Chugai Pharma; Daiichi Sankyo; Kyowa Kirin International; Lilly; Pfizer
 
Toshikazu Fukami
Employment - Tech Doctor Inc.
 
Mako Ikeda
No Relationships to Disclose
 
Hiroaki Kato
No Relationships to Disclose
 
Takashi Morimoto
No Relationships to Disclose
 
Kentaro Tamaki
No Relationships to Disclose
 
Mitsugu Yamamoto
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo; MSD; Pfizer
 
Takuho Okamura
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Kirin; Lilly; MSD; Nipro Corporation
 
Tetsuhiko Taira
Honoraria - Chugai Pharma; Daiichi Sankyo; Gilead Sciences; Hisamitsu Pharmaceutical; Lilly; MSD; Novartis; Pfizer; Taiho Pharmaceutical
 
Noriko Maeda
No Relationships to Disclose
 
Koji Matsumoto
Consulting or Advisory Role - Daiichi Sankyo; Gilead Sciences K.K.; Pfizer
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly Japan; MSD
Research Funding - Ascent Development Services (Inst); Astrazeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences K.K. (Inst); Lilly Japan (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
 
Akihiko Shimomura
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Exact Sciences; Gilead Sciences; Kyowa Kirin International; Lilly; MSD K.K; Pfizer
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); MSD K.K (Inst); Pfizer (Inst)
 
Taiyu Sumida
Consulting or Advisory Role - Daiichi Sankyo (Inst)
Research Funding - Daiichi Sankyo (Inst)
 
Akifumi Kurata
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Tadahiro Izutani
Employment - Daiichi Sankyo Co., Ltd
 
Naoki Niikura
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly Japan; MSD; Novartis; Pfizer
Research Funding - Chugai Pharma; Daiichi Sankyo; Eisai; Mochida Pharmaceutical Co. Ltd. (Inst); Novartis (Inst); Pfizer
 
Yuichiro Kikawa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical